Healthcare Business Intelligence Market Size to Reach USD 27.63 Billion By 2032, With a Growing CAGR of 14% | Research by SNS Insider
August 14, 2024 08:54 ET
|
SNS Insider pvt ltd
Pune, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Healthcare Business Intelligence Market Size & Share: “According to SNS Insider Research, The Healthcare Business Intelligence (BI) Market Size was...
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
August 14, 2024 08:30 ET
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
August 14, 2024 08:30 ET
|
Oragenics
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics,...
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
August 14, 2024 08:30 ET
|
RenovoRx, Inc.
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout...
AI in Drug Discovery Market: $0.9B to $4.9B Growth Forecast (2023-2028) | MarketsandMarkets™
August 14, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The "AI in Drug Discovery Market Size, Share & Trends by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design...
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
August 14, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine) Sublingual Film to the FDA in the...
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
ScribeAmerica Announces Expansion of Speke AI Service Line
August 14, 2024 08:00 ET
|
ScribeAmerica.
FORT LAUDERDALE, FLORIDA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ScribeAmerica announces today an expansion of their AI-powered clinical documentation service, Speke, that continues their focus on...
Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
August 14, 2024 07:30 ET
|
Veralox Therapeutics
Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
August 14, 2024 07:30 ET
|
Atsena Therapeutics
Priority Review Voucher would be issued upon approval of ATSN-201 Second RPD and potential PRV for Atsena’s ocular gene therapy portfolio DURHAM, N.C., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Atsena...